False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland

Matthew A Crane; Michael J DiStefano; Thomas J Moore

doi:10.1001/jamanetworkopen.2023.42210

False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland

JAMA Netw Open. 2023 Nov 1;6(11):e2342210. doi: 10.1001/jamanetworkopen.2023.42210.

Authors

Matthew A Crane¹, Michael J DiStefano², Thomas J Moore³

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
³ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

No abstract available

Plain language summary

This cross-sectional study evaluates the prevalence of false or misleading information in online direct-to-consumer advertising for off-label and unapproved ketamine in Maryland.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Advertising
Humans
Ketamine*
Maryland

Substances

Ketamine